알츠하이머 초조증 비항정신병 약물 치료 시장 보고서(2026년)

Alzheimer's agitation non-antipsychotic drug therapy refers to pharmaceutical approaches used to manage agitation, aggression, and associated behavioral symptoms in individuals with Alzheimer's disease without the use of antipsychotic medications. These therapies work by influencing neurotransmitter activity and neurobiological pathways associated with mood, behavior, and cognitive regulation to improve symptom management. Alzheimer's agitation non-antipsychotic drug therapies aim to provide safer treatment alternatives to antipsychotics by minimizing risks such as sedation, cognitive impairment, and cardiovascular complications.

The primary drug classes of Alzheimer's agitation non-antipsychotic drug therapy include N-methyl-D-aspartate receptor antagonists, sigma-one receptor agonists, serotonin modulators, and novel central nervous system targets. N-methyl-D-aspartate receptor antagonists refer to therapeutic agents that regulate glutamate activity in the brain to help manage agitation symptoms associated with Alzheimer's disease. These therapies are designed for patient settings including memory care facilities, home care, assisted living, and hospital inpatient settings and address disease stages such as mild to moderate Alzheimer's and moderate to severe Alzheimer's. They are administered through routes including oral, injectable, transdermal, and intranasal and are utilized by end users including hospitals, neurology clinics, geriatric care centers, rehabilitation centers, and home healthcare providers.

Tariffs are influencing the Alzheimer's agitation non-antipsychotic drug therapy market by increasing the cost of imported active pharmaceutical ingredients, biologic materials, laboratory equipment, and specialized drug manufacturing components required for therapy development and production. This is creating supply chain disruptions and increasing production expenses across pharmaceutical and biotechnology ecosystems, particularly in regions dependent on imported healthcare materials such as North America, Europe, and Asia-Pacific. Drug-intensive segments such as serotonin modulators, sigma-one receptor agonists, and novel central nervous system targets are most affected due to their dependence on globally sourced ingredients and research inputs. However, tariffs are also encouraging local pharmaceutical manufacturing expansion, regional supplier diversification, and increased investments in domestic drug development ecosystems, creating stronger long-term market resilience.

The alzheimer's agitation non-antipsychotic drug therapy market research report is one of a series of new reports from The Business Research Company that provides alzheimer's agitation non-antipsychotic drug therapy market statistics, including alzheimer's agitation non-antipsychotic drug therapy industry global market size, regional shares, competitors with a alzheimer's agitation non-antipsychotic drug therapy market share, detailed alzheimer's agitation non-antipsychotic drug therapy market segments, market trends and opportunities, and any further data you may need to thrive in the alzheimer's agitation non-antipsychotic drug therapy industry. This alzheimer's agitation non-antipsychotic drug therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The alzheimer's agitation non-antipsychotic drug therapy market size has grown rapidly in recent years. It will grow from $5.09 billion in 2025 to $5.85 billion in 2026 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to rising prevalence of alzheimer's disease globally, increasing geriatric population growth, growing awareness regarding behavioral symptoms in dementia care, expansion of neurological research activities, increasing concerns regarding antipsychotic related adverse effects.

The alzheimer's agitation non-antipsychotic drug therapy market size is expected to see rapid growth in the next few years. It will grow to $9.98 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to growing investments in neurodegenerative disease drug development, increasing demand for precision medicine approaches, rising clinical research for novel neurobehavioral therapies, expansion of home based dementia care services, increasing regulatory support for safer treatment alternatives. Major trends in the forecast period include increasing development of safer alternatives to antipsychotic therapies, growing focus on targeted neurobehavioral symptom management, rising adoption of multimodal therapeutic approaches for agitation treatment, increasing research on neurotransmitter pathway modulation therapies, expansion of clinical trials for novel central nervous system therapies.

The increasing prevalence of Alzheimer's disease is expected to drive the growth of the Alzheimer's agitation non-antipsychotic drug therapy market going forward. Alzheimer's disease is a progressive neurodegenerative condition that gradually affects memory, cognitive abilities, and behavior due to the deterioration and loss of brain cells. The growing prevalence of Alzheimer's disease is attributed to rising life expectancy, as an expanding elderly population increases the number of individuals reaching age groups with a higher risk of developing the condition. Alzheimer's agitation non-antipsychotic drug therapy helps manage behavioral and psychological symptoms associated with Alzheimer's disease, enhancing patient care, improving quality of life, and supporting better long-term care outcomes for the increasing patient population. For instance, in December 2025, according to the Australian Government, an Australian-based government department, approximately 25,000 people in Australia were living with dementia, including nearly 266,000 women and 159,000 men, representing around 16 cases per 1,000 Australians (19 per 1,000 women and 12 per 1,000 men). Therefore, the increasing prevalence of Alzheimer's disease is driving the growth of the Alzheimer's agitation non-antipsychotic drug therapy market.

The increasing investments in research and development are expected to drive the growth of the Alzheimer's agitation non-antipsychotic drug therapy market going forward. Research and development investments refer to the allocation of financial resources by governments, pharmaceutical companies, and academic organizations toward the discovery, development, and clinical evaluation of new therapeutic solutions. The growth in R&D investments is primarily fueled by the rising global burden of Alzheimer's disease, as an increasing aging population expands the number of patients requiring targeted therapies, creating greater demand for effective non-antipsychotic treatment approaches. Increased R&D funding supports the discovery and clinical validation of innovative non-antipsychotic compounds that specifically target agitation symptoms in Alzheimer's patients, strengthening the therapeutic pipeline and enabling the introduction of new treatment options. For instance, in February 2025, according to the National Center for Science and Engineering Statistics (NCSES), a US-based government statistical agency, U.S. research and development expenditures increased from $892 billion in 2022 to $940 billion in 2023, representing a rise of $48 billion. Therefore, increasing research and development investments are driving the growth of the Alzheimer's agitation non-antipsychotic drug therapy market.

Major companies operating in the Alzheimer's agitation non-antipsychotic drug therapy market are focusing on developing advanced non-antipsychotic treatments to manage agitation symptoms associated with Alzheimer's disease while reducing the safety risks associated with conventional antipsychotic medications. Non-antipsychotic therapies are treatments that address agitation through alternative neurological pathways without using antipsychotic mechanisms, potentially providing improved safety and tolerability for elderly patients. For instance, in April 2026, Axsome Therapeutics, a US-based biopharmaceutical company, received U.S. FDA approval for Auvelity (dextromethorphan-bupropion) for treating agitation associated with dementia caused by Alzheimer's disease. The approval marked the introduction of the first FDA-approved non-antipsychotic therapy for this indication, providing a new treatment approach for managing agitation symptoms. The therapy acts on NMDA and sigma-1 receptors, expanding available treatment options for patients and caregivers.

Major companies operating in the alzheimer's agitation non-antipsychotic drug therapy market report are Axsome Therapeutics Inc., Bristol Myers Squibb Company, Suven Life Sciences Limited, IGC Pharma Inc., Exciva GmbH, Neumora Therapeutics Inc.

North America was the dominating region in the alzheimer's agitation non-antipsychotic drug therapy market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the alzheimer's agitation non-antipsychotic drug therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the alzheimer's agitation non-antipsychotic drug therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The alzheimer's agitation non-antipsychotic drug therapy market consists of sales of mirtazapine, gabapentin, pregabalin, suvorexant, ramelteon, and melatonin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses alzheimer's agitation non-antipsychotic drug therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for alzheimer's agitation non-antipsychotic drug therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The alzheimer's agitation non-antipsychotic drug therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Class: N Methyl D Aspartate Receptor Antagonists; Sigma One Receptor Agonists; Serotonin Modulators; Novel Central Nervous System Targets
• 2) By Patient Setting: Memory Care Facilities; Home Care; Assisted Living; Hospital Inpatient
• 3) By Disease Stage: Mild To Moderate Alzheimer's; Moderate To Severe Alzheimer's
• 4) By Route Of Administration: Oral; Injectable; Transdermal; Intranasal
• 5) By End User: Hospitals; Neurology Clinics; Geriatric Care Centers; Rehabilitation Centers; Home Healthcare Providers
• Subsegments:
• 1) By N Methyl D Aspartate Receptor Antagonists: Uncompetitive Channel Blockers; Glycine Site Antagonists; Subunit Selective Antagonists; Low Affinity Glutamate Receptor Blockers
• 2) By Sigma One Receptor Agonists: Selective Sigma One Receptor Agonists; Multimodal Antidepressant Sigma Activity Agents; Dual Receptor Neurobehavioral Modulators; Neuroprotective Sigma Pathway Agonists
• 3) By Serotonin Modulators: Serotonin Reuptake Inhibition Modulators; Serotonin Receptor Partial Agonists; Serotonin Receptor Antagonist Modulators; Multimodal Serotonergic Agents
• 4) By Novel Central Nervous System Targets: Orexin Pathway Modulators; Gamma Aminobutyric Acid System Modulators; Glutamatergic Metabotropic Receptor Modulators; Neuroinflammation Pathway Modulators; Cannabinoid Receptor Modulators
• Companies Mentioned: Axsome Therapeutics Inc.; Bristol Myers Squibb Company; Suven Life Sciences Limited; IGC Pharma Inc.; Exciva GmbH; Neumora Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Immersive Technologies (AR/VR/XR) & Digital Experiences
• 4.2. Major Trends
  • 4.2.1 Increasing Development Of Safer Alternatives To Antipsychotic Therapies
  • 4.2.2 Growing Focus On Targeted Neurobehavioral Symptom Management
  • 4.2.3 Rising Adoption Of Multimodal Therapeutic Approaches For Agitation Treatment
  • 4.2.4 Increasing Research On Neurotransmitter Pathway Modulation Therapies
  • 4.2.5 Expansion Of Clinical Trials For Novel Central Nervous System Therapies

5. Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Neurology Clinics
• 5.3 Geriatric Care Centers
• 5.4 Home Healthcare Providers
• 5.5 Other End Users

6. Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Alzheimer's Agitation Non-Antipsychotic Drug Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Alzheimer's Agitation Non-Antipsychotic Drug Therapy PESTEL Analysis (Political, Economical, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Alzheimer's Agitation Non-Antipsychotic Drug Therapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Alzheimer's Agitation Non-Antipsychotic Drug Therapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Alzheimer's Agitation Non-Antipsychotic Drug Therapy Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Segmentation

• 9.1. Global Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• N Methyl D Aspartate Receptor Antagonists, Sigma One Receptor Agonists, Serotonin Modulators, Novel Central Nervous System Targets
• 9.2. Global Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Patient Setting, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Memory Care Facilities, Home Care, Assisted Living, Hospital Inpatient
• 9.3. Global Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Mild To Moderate Alzheimer's, Moderate To Severe Alzheimer's
• 9.4. Global Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Injectable, Transdermal, Intranasal
• 9.5. Global Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Neurology Clinics, Geriatric Care Centers, Rehabilitation Centers, Home Healthcare Providers
• 9.6. Global Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Sub-Segmentation Of N Methyl D Aspartate Receptor Antagonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Uncompetitive Channel Blockers, Glycine Site Antagonists, Subunit Selective Antagonists, Low Affinity Glutamate Receptor Blockers
• 9.7. Global Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Sub-Segmentation Of Sigma One Receptor Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Selective Sigma One Receptor Agonists, Multimodal Antidepressant Sigma Activity Agents, Dual Receptor Neurobehavioral Modulators, Neuroprotective Sigma Pathway Agonists
• 9.8. Global Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Sub-Segmentation Of Serotonin Modulators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Serotonin Reuptake Inhibition Modulators, Serotonin Receptor Partial Agonists, Serotonin Receptor Antagonist Modulators, Multimodal Serotonergic Agents
• 9.9. Global Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Sub-Segmentation Of Novel Central Nervous System Targets, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Orexin Pathway Modulators, Gamma Aminobutyric Acid System Modulators, Glutamatergic Metabotropic Receptor Modulators, Neuroinflammation Pathway Modulators, Cannabinoid Receptor Modulators

10. Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Regional And Country Analysis

• 10.1. Global Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 11.1. Asia-Pacific Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 12.1. China Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 13.1. India Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 14.1. Japan Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 15.1. Australia Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 16.1. Indonesia Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 17.1. South Korea Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 18.1. Taiwan Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 19.1. South East Asia Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 20.1. Western Europe Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 21.1. UK Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 22.1. Germany Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 23.1. France Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 24.1. Italy Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 25.1. Spain Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 26.1. Eastern Europe Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 27.1. Russia Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 28.1. North America Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 29.1. USA Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 30.1. Canada Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 31.1. South America Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 32.1. Brazil Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 33.1. Middle East Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

• 34.1. Africa Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market, Segmentation By Drug Class, Segmentation By Patient Setting, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Regulatory and Investment Landscape

36. Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Competitive Landscape And Company Profiles

• 36.1. Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Company Profiles
  • 36.3.1. Axsome Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Suven Life Sciences Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. IGC Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Exciva GmbH Overview, Products and Services, Strategy and Financial Analysis

37. Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Other Major And Innovative Companies

• Neumora Therapeutics Inc.

38. Global Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

41. Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market High Potential Countries, Segments and Strategies

• 41.1 Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market In 2030 - Countries Offering Most New Opportunities
• 41.2 Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market In 2030 - Segments Offering Most New Opportunities
• 41.3 Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market In 2030 - Growth Strategies
  • 41.3.1 Market Trend Based Strategies
  • 41.3.2 Competitor Strategies

42. Appendix

• 42.1. Abbreviations
• 42.2. Currencies
• 42.3. Historic And Forecast Inflation Rates
• 42.4. Research Inquiries
• 42.5. The Business Research Company
• 42.6. Copyright And Disclaimer